Bevacizumab's Impact Felt Despite Lack Of Clinical Data

OSN SuperSite

NEW ORLEANS — Citing the downturn in sales of verteporfin and pegaptinib, a surgeon speaking here explained how bevacizumab has greatly impacted age-related macular degeneration treatment, despite the fact that is has not gained U.S. approval for treating the disease and the lack of clinical trial data to support its use.